These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9098882)

  • 1. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes.
    Séjourné F; Rubinstein I; Suzuki H; Alkan-Onyüksel H
    Pharm Res; 1997 Mar; 14(3):362-5. PubMed ID: 9098882
    [No Abstract]   [Full Text] [Related]  

  • 2. Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch.
    Ikezaki H; Paul S; Alkan-Onyüksel H; Patel M; Gao XP; Rubinstein I
    Am J Physiol; 1998 Jul; 275(1):R56-62. PubMed ID: 9688960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo.
    Séjourné F; Suzuki H; Alkan-Onyüksel H; Gao XP; Ikezaki H; Rubinstein I
    Am J Physiol; 1997 Jul; 273(1 Pt 2):R287-92. PubMed ID: 9249562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure.
    Gao XP; Noda Y; Rubinstein I; Paul S
    Life Sci; 1994; 54(15):PL247-52. PubMed ID: 8152324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformation and vasoreactivity of VIP in phospholipids: effects of calmodulin.
    Rubinstein I; Patel M; Ikezaki H; Dagar S; Onyüksel H
    Peptides; 1999 Dec; 20(12):1497-501. PubMed ID: 10698126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilation in vivo.
    Suzuki H; Noda Y; Paul S; Gao XP; Rubinstein I
    Life Sci; 1995; 57(15):1451-7. PubMed ID: 7674836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo.
    Ikezaki H; Onyüksel H; Rubinstein I
    Am J Physiol; 1998 Aug; 275(2):R588-95. PubMed ID: 9688697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal vasoactive intestinal peptide.
    Sethi V; Onyüksel H; Rubinstein I
    Methods Enzymol; 2005; 391():377-95. PubMed ID: 15721392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ.
    Suzuki H; Noda Y; Gao XP; Séjourné F; Alkan-Onyuksel H; Paul S; Rubinstein I
    Am J Physiol; 1996 Jul; 271(1 Pt 2):H282-7. PubMed ID: 8760186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
    Rubinstein I; Ikezaki H; Onyüksel H
    Int J Pharm; 2006 Jun; 316(1-2):144-7. PubMed ID: 16580160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo.
    Rubinstein I; Ashok B; Tsueshita T; Onyüksel H
    Peptides; 2005 Mar; 26(3):509-15. PubMed ID: 15652658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.
    Reichstetter S; Castillo GM; Rubinstein I; Nishimoto-Ashfield A; Lai M; Jones CC; Banerjee AA; Lyubimov A; Bloedow DC; Bogdanov A; Bolotin EM
    Pharm Res; 2013 Mar; 30(3):670-82. PubMed ID: 23224976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles.
    Ashok B; Rubinstein I; Tsueshita T; Onyüksel H
    Peptides; 2004 Aug; 25(8):1253-8. PubMed ID: 15350692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutral endopeptidase modulates VIP-induced vasodilation in hamster cheek pouch vessels in situ.
    Suzuki H; Gao XP; Olopade CO; Rubinstein I
    Am J Physiol; 1996 Aug; 271(2 Pt 2):R393-7. PubMed ID: 8770140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal VIP potentiates DNA synthesis in cultured oral keratinocytes.
    Rubinstein I; Dagar S; Sethi V; Krishnadas A; Onyüksel H
    Peptides; 2001 Apr; 22(4):671-5. PubMed ID: 11311738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of quinupristin/dalfopristin on vasomotor tone in the intact peripheral microcirculation.
    Tsueshita T; Gandhi S; Rubinstein I
    J Antimicrob Chemother; 2002 Jun; 49(6):1027-30. PubMed ID: 12039898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glucagon, vasoactive intestinal peptide (VIP) and lysine-vasopressine on villous microcirculation and superior mesenteric artery blood flow of the rat.
    Holliger C; Radzyner M; Villiger A; Anliker M; Knoblauch M
    Bibl Anat; 1979; (18):129-31. PubMed ID: 496810
    [No Abstract]   [Full Text] [Related]  

  • 18. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis.
    Lajavardi L; Camelo S; Agnely F; Luo W; Goldenberg B; Naud MC; Behar-Cohen F; de Kozak Y; Bochot A
    J Control Release; 2009 Oct; 139(1):22-30. PubMed ID: 19481575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity.
    Onyüksel H; Ashok B; Dagar S; Sethi V; Rubinstein I
    Peptides; 2003 Feb; 24(2):281-6. PubMed ID: 12668213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous calmodulin potentiates vasodilation elicited by phospholipid-associated VIP in vivo.
    Ikezaki H; Patel M; Onyüksel H; Akhter SR; Gao XP; Rubinstein I
    Am J Physiol; 1999 May; 276(5):R1359-65. PubMed ID: 10233028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.